Product

TU2218

Name

TU2218

1 clinical trial

1 indication

Indication

Advanced Solid Tumor

Clinical trial

A Phase 1/2 Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TU2218, an Oral TGFβR Inhibitor, Administered Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Status: Recruiting, Estimated PCD: 2026-06-30